ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine the safety and tolerability of the
combination of Zactima with metronomic chemotherapy. Zactima is an oral anti-angiogenesis
drug, which means it fights cancer by cutting off a tumor's blood supply. Thus, the drug
starves the tumor by preventing the delivery of nutrients and oxygen. Metronomic chemotherapy
is low dose oral chemotherapy pills which are taken daily. Unlike traditional chemotherapy,
metronomic chemotherapy is thought to fight cancer like Zactima, by cutting off the blood
supply to tumors. Because the dose is very low, the side effects are generally mild and very
different from those with higher dose chemotherapy given by vein.
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
AstraZeneca Brigham and Women's Hospital Massachusetts General Hospital